Recommendations of the Spanish Society of Nephrology for managing bone-mineral metabolic alterations in chronic kidney disease patients (S.S.N.-MM);Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica (S.E.N.-MM)

Nefrologia

Volumn 31, Issue SUPPL.1, 2011, Pages 3-32

  Torregrosa, José Vicente ^a   Bover, Jordi ^b   Andía, Jorge Cannata ^c   Lorenzo, Víctor ^d   de Francisco, Ángel Luis Martín ^e   Martínez, Isabel ^f   Portillo, Mariano Rodríguez ^g   Arenas, Lola ^h   Parra, Emilio González ⁱ   Caravaca, Francisco ^j   Martín Malo, Alejandro ^g   Giráldez, Elvira Fernández ^k   Torres, Armando ^l  

^a HOSPITAL CLÍNIC   (Spain)

^b FUNDACIÓ PUIGVERT   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d Hospital Clínico Universitario   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f Hospital Universitario Galdakao   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h HOSPITAL PERPETUO SOCORRO   (Spain)

ⁱ Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^j HOSPITAL INFANTA CRISTINA   (Spain)

^k HOSPITAL ARNAU DE VILANOVA   (Spain)

^l INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; CALCIUM; CELL SURFACE RECEPTOR; MINERAL; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

ALGORITHM; ARTICLE; BONE REMODELING; CALCINOSIS; CHELATION THERAPY; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; DIAGNOSTIC IMAGING; DIET THERAPY; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; METABOLIC BONE DISEASE; METABOLISM; MULTIMODALITY CANCER THERAPY; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REFERENCE VALUE; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM;

ALGORITHMS; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE REMODELING; CALCINOSIS; CALCIPHYLAXIS; CALCIUM; CHELATION THERAPY; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MINERALS; PARATHYROID HORMONE; PARATHYROIDECTOMY; PHOSPHORUS; RECEPTORS, CELL SURFACE; REFERENCE VALUES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D;

EID: 79952058422     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Jan.10816     Document Type: Article

References (137)

1. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;421-201.
2. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am J Kidney Dis 2000;35(suppl 2):S1-S140.
3. Moe S, Drueke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-53.
4. Moe SM, Drüeke TB, Block GA, et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group Kidney Int Suppl. 2009;(113):S1-130.
5. Llach F, Bover J. Renal Osteodystrophies. En: Brenner BM (ed.). The Kidney (6th ed.). Philadelphia: W.B. Saunders Company, 2000;2103-186.
6. Martínez I, Saracho R, Montenegro J, Llach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996;11(Supl 3):22-8.
7. Hsu CH, Patel SR. Uremic toxins and vitamin D metabolism. Kidney Int 1997;62:s65-8.
8. Rodriguez ME, et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Renal Physiol 2007;292:390-5.
9. Carrillo-López N, Álvarez-Hernández D, González-Suárez I, et al. Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol. Nephrol Dial Transplant 2008;23(11):3479-84.
10. Mendoza FJ, Lopez I, Montes de Oca A, et al. Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney Int 2008;73(4):407-14.
11. Qunibi WY. Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int 2004;90:S8-S12.
12. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8.
13. Stevens LA, Djurdjev O, Cardew S, et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004;15:770-99.
14. Block GA, Cunningham J. Morbidity and mortality associated with abnormalities in bone and mineral metabolism in CKD. En: Olgaard K (ed.). Clinical Guide to the Basics of Bone and Mineral Metabolism in CKD. New York: National Kidney Foundation, 2006;4:77-92.
15. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000;35(6):1226-37.
16. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;5(8):2208-18.
17. Cunningham J. Osteoporosis in Chronic Kidney Disease. Am J Kidney Dis 2004;43:566-71.
18. Rodríguez-Benot A, Martín-Malo A, Álvarez-Lara MA, Rodríguez M, Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005;46:68-77.
19. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8.
20. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004;15:770-9.
21. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS Waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-93.
22. Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004;43:558-65.
23. Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, Cukketon BF. Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology: Mineral Metabolism. J Am Soc Nephrol 2006;17(Suppl 1):S11-S16.
24. González Parra E, Arenas MD, Valencia J, Angoso M. Monitorización del paciente en hemodiálisis. Nefrologia 2006;26(Sup 8):34-53.
25. Gauci C, Morante O, Fouqueray B, et al. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol 2008;19(8):1592-8.
26. Monfort M, Delanaye P, Chapelle JP, et al. Plasma calcium in haemodialysis patients: total calcium or ionized calcium? Should we systematically provide a value of total corrected calcium on our protocols? Ann Biol Clin (Paris) 2008;66(5):573-6.
27. Ferrari P, Singer R, Agarwal A, et al. Serum phosphate is an important determinant of corrected serum calcium in end-stage kidney disease. Nephrology (Carlton) 2009;14(4):383-8.
28. Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995;47:1434-42.
29. De la Piedra C, Fernandez E, Gonzalez Casaus ML, et al. Different biological functions in PTH molecules. What are we measuring? Nefrologia 2008;28(2):123-8.
30. Fehr T, Garzón D, Staub T, et al. Measurement of PTH fragments for assessment of renal bone disease in hemodialysis patients. Kidney Blood Press Res 2006;29(3):175-81.
31. Gómez Alonso C, Naves Díaz ML, Fernández Martín JL, et al. Vitamin D status and secondary hyperparathyroidism: The importance of 25-hydroxy vitamin D cut-off levels. Kidney Int 2003;63(suppl 85):S44-S48.
32. Autier P, et al. Vitamin D supplementation and Total Mortality. A meta-analysis of randomized controlled trials. Arch Int Med 2007;167(16):1730-7.
33. Dusso A, Arcidiacono MV, Yang J, et al. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol 2010;121(1-2):193-8.
34. Matías PJ, Jorge C, Ferreira C, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010;5(5):905-11.
35. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72(8):1004-13.
36. Michaud J, Naud J, Ouimet D, et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol 2010;21(9):1488-97.
37. Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008;19(11):2193-203.
38. Shantouf R, Kovesdy CP, Kim Y, et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2009;4(6):1106-14.
39. Adragao T, et al. A simple vascular calcification score predicts cardiovascular risk in hemodialysis patients. Nephrol Dial Transplant 2004;19: 1480-8.
40. Bellasi A, Raggi P. Techniques and technologies to assess vascular calcification. Semin Dial 2007;20(2):129-33.
41. Yamaguchi T, et al. Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 1996;19:549-55.
42. Ureña P, et al. Bone mineral density, biochemical markers and skeletal fractures in hemodialysis patients. Nephrol Dial Transplant 2003;18:2325-31.
43. Muxí A, Torregrosa JV, Fuster D, et al. Arteriovenous fistula affects bone mineral density measurements in end-stage renal failure patients. Clin J Am Soc Nephrol 2009;4(9):1494-9.
44. Kopple JD, et al. Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney Int 1997;52(3):778-91.
45. Rufino M, Lorenzo V, et al. Is it possible to control hyperphosphatemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 1998;13(Suppl 3):65-7.
46. Lorenzo V, Torres A. Tratamiento Conservador de la Insuficiencia Renal Crónica. Medidas generales y manejo dietético. En: Hernando L (ed.). Nefrología Clínica. Madrid: Editorial Panamericana, 1997.
47. Lorenzo V, Rufino M, Martín M. Aspectos nutricionales en hemodiálisis. En: Valderrábano F (ed.). Tratado de Hemodiálisis. Barcelona: Editorial Médica JIMS S.L., 1999;339-49.
48. Martínez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997;29(4):496-502.
49. Martínez I, Saracho R, Ocharan J, Muñoz RJ, Montenegro J. Role of diet in the management of osteodystrophy during progressive renal insufficiency. Nefrologia 2003;23(Suppl 2):57-63.
50. Giovannucci E. Can vitamin D reduce total mortality? Arch Intern Med 2007;167(16):1709-10.
51. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment of vitamin D. Am J Clin Nutr 2007;85(1):6-18.
52. Wolf M, Shah A, Gutierrez O, et al. Vitamin D leevls and early mortality among inident hemodialysis patients. Kidney Int 2007.
53. Torregrosa JV, Ramos AM. Use of bisphosphonates in chronic kidney disease. Nefrologia 2010;30(3):288-96.
54. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005;289:8-28.
55. Shoben AB, Rudser KD, De Boer IH, et al. Association of oral calcitriol with improved survival in nondialyzed CKD.J Am Soc Nephrol 2008;19(8).
56. Naves Díaz M, Álvarez Hernández D, Passlick Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008;74:1070-8.
57. Sugiura S, Inaguma D, Kitagawa A, et al. Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol 2010;14:43-50.
58. Reichel H. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease. Nephron Clin Pract 2010;114:268-76.
59. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006;69:33-43.
60. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56.
61. Cardus A, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860-6.
62. Charra B, Chazot C, Jean G et al. Long 3 x 8 hr dialysis: a threedecade summary. J Nephrol 2003;(S7):S64-S69.
63. Leypoldt JK. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration. Semin Dial 2005;18: 401-8.
64. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998;53:1399-404.
65. Sigrist MK, Devlin L, Taal MW, Fluck RJ, McIntyre CW. Length of interdialytic interval influences serum calcium and phosphorus concentrations. Nephrol Dial Transplant 2005;20:1643-6.
66. Lindsay RM, Al-Hejaili F, Nesrallah G. Calcium and phosphate balance with quotidian hemodialysis. Am J Kidney Dis 2003;42(Suppl 1):S24-S29.
67. Walsh M, Culleton B, Tonelli M, Manns B. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 2005;67:1500-8.
68. Maduell F, Navarro V, Torregrosa E, et al. Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int 2003;64:305-13.
69. Zehnder C, Gutzwiller JP, Renggli K. Hemodiafiltration-a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 1999;52:152-9.
70. Locatelli F, Buoncristiani U, Canaud B, Kohler H, Petitclerc T, Zucchelli P. Dialysis dose and frequency. Nephrol Dial Transplant 2005;20:285-96.
71. Almirall J, Valenzuela MP. The safety of phosphate binders. Expert Opin Drug Saf 2006;5:675-86.
72. Schucker JJ, Ward KE. Hyperphosphatemia and phosphate binders. Am J Health Syst Pharm 2005;62:2355-61.
73. Qunibi W, Muenz LR. Progression of calcification in the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. Am J Kidney Dis 2008;52(5):1022-3.
74. Floege J. Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them? Nephrol Dial Transplant 2008;23(10):3050-2.
75. Block GA, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41.
76. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-basel phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7.
77. Freemont AJ. Lanthanum carbonate. Drugs Today 2006;42:759-70.
78. Curran MP, Robinson DM. Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease. Drugs 2009;69(16):2329-49.
79. Wilson R, Zhang P, Smyth M, Pratt R. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 2009;25(12):3021-8.
80. De Francisco ALM, Leidig M, Covic AC, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25(11):3707-17.
81. Spiegel DM, Farmer B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study.Hemodial Int 2009;13(4):453-9.
82. Block GA, Martin KJ, De Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
83. De Francisco ALM. Cinacalcet HCL: a novel therapeutic for hyperparathyroidism. Exp Opin Pharmacother 2005;6:441-52.
84. Schmitt CP, Odenwald T, Ritz E. Calcium, calcium regulatory hormones, and calcimimetics: impact on cardiovascular mortality. J Am Soc Nephrol Apr;17(4):S78-pubmed.
85. Block GA, Martin KJ, De Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350(15):1516-25.
86. Mlittman N, Finkelstein F, Culleton B, et al. Cinacalcet HCl (Sensipar ®) for the Management of Secondary Hyperparathyroidism (HPT) in Patients Receiving Peritoneal Dialysis (PD). J Am Soc Nephrol 2004;15:280.
87. Chertow GM, Blumenthal S, Turner S, et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 2006;1(2):305-12.
88. Bover J, Perez R, Molina M, et al. Cinacalcet Treatment for Secondary Hyperparathyroidism in Dialysis Patients: An Observational Study in Routine Clinical Practice. Nephron Clin Pract 2010;118(2):109-21.
89. López I, Mendoza FJ, Guerrero F, et al. The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. Am J Physiol Renal Physiol 2009;296(6):F1376-85.
90. Torres A, Rodríguez AP, Concepción MT, García S, Rufino M, Martín B, et al. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998;13:94-7.
91. Egbuna OI, Taylor JG, Bushinsky DA. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007;21:558.
92. Evenpoel P, Naesens M, Claes K. Tertiary hyperphosphatonism accentuates hypophosphatemia and suppresses Calcitriol levels in renal transplant recipients. Am J Transplant 2007;7:1193-200.
93. Gwinner W, Suppa S, Mengel M, Hoy L, Kreipe HH, Haller H, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005;5:1934-41.
94. Triponez F, Clark OH, Vanrenthergem Y, Evenepoel P. Surgical treatment of persistent hyperparathyroidism after renal transplantation. Ann Surg 2008;248:18-30.
95. Serra AL, Schwarz AA, Wick FH. Succesful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparthyroidism. Nephrol Dial Transplant 2005;20:1315-7.
96. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005;20:1311-4.
97. Szwarc I, Argiles A, Garrigue V, Delmas S, Chong G, Deleuze S, et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Nephron Dial Transplant 2006;82(5):675-80.
98. Srinivas TR, Schold JD, Womer KL, et al. Improvement in Hypercalcemia with Cinacalcet after Kidney Transplantation. Clin J Am Soc Nephrol 2006;1:323-6.
99. Serra AL, Savoca R, Huber AR, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007;22(2):577-83.
100. Bergua C, Torregrosa JV, Fuster D, Gutiérrez-Dalmau A, Oppenheimer F, Campistol JM. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008;86:413-7.
101. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantatuion. J Am Soc Nephrol 2002;13:551-8.
102. Wisinger JR, Carlini RG, Rojas E, Bellorin-Font E. Bone disease after renal transplantation. Clin J Am Soc Nephrol 2006;1:1300-13.
103. Carlini RG, Rojas E, Weisinger JR, Lopez M, Martinis R, Arminio A, et al. Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 2000;36:160-5.
104. Cunningham J. Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression. J Am Soc Nephrol 2007;18(1):223-34.
105. Nikkel LE, Hollenbeak CS, Fox EJ, Uemura T, Ghahramani N. Risk of fractures after renal transplantation in the United States. Transplantation 2009;87(12):1846-51.
106. Akaberi S, Simonsen O, Lindergård B, Nyberg G. Can DXA predict fractures in renal transplant patients? Am J Transplant 2008;8(12):2647-51.
107. Mazzaferro S, Diacinti D, Proietti E, Barresi G, Baldinelli M, Pisani D, et al. Morphometric X-ray absorptiometry in the assessment of vertebral fractures in renal transplant patients. Nephrol Dial Transplant 2006;21(2):466-71.
108. Torres A, García S, Gómez A, et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 2004;65:705-12.
109. De Sevaux RG, Hoitsma AJ, Crstens FH, et al. Treatment with vitamin D y calcium reduces bone loss after renal transplantation: A randomized study. J Am Soc Nephrol 2002;13:1608-14.
110. El-Agroudy AE, El-Husseini AA, El-Sayed M, et al. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol 2003;14:2975-9.
111. Josephson MA, Schumm LP, Chiu MY, et al. Calcium and calcitriol prophylaxis attenuates postransplant bone loss. Transplantation 2004;78:1233-6.
112. Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2007;Jul 18;(3):CD005015.
113. Torregrosa JV, Fuster D, Pedroso S, Diekmann F, Campistol JM, Rubí S, et al. Weekly risedronate in kidney transplant patients with osteopenia. Transpl Int 2007;20(8):708-11.
114. Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 2009;4(1):221-33.
115. Coco M, Glicklich D, Claude M, et al. Prevention of Bone Loss in Renal Transplant Recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003;14:2669-76.
116. Fan SLS, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 2000;57:684-90.
117. Grotz W, Nagel Ch, Poeschel D, et al. Effect of Ibandronate on Bone Loss and Renal Function after Kidney Transplantation. J Am Soc Nephrol 2001;12:1530-7.
118. Giannini S, Dangel A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 2001;16:2111-7.
119. Torregrosa JV, Moreno A, Gutiérrez A, et al. Alendronate for treatment of renal transplant patients with osteoporosis. Transp Proc 2003;35(4):1393-5.
120. Torregrosa JV, Fuster D, Gentil MA, et al. Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients. Transplantation 2010;89(12):1476-81.
121. Torregrosa JV, Fuster D, Monegal A, et al. Efficacy of low doses of pamidronate in osteopenic patients administered in the early postrenal transplant. Osteoporos Int 2011;22(1):281-7.
122. Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 2008;8(9):1864-70.
123. Lehmann G, Ott U, Maiwald J, Wolf G. Bone histomorphometry with teriparatide (PTH 1-34) in a patient with adynamic bone disease subsequent to parathyroidectomy. Nephrol Dial Transplant Plus 2009;1:49-51.
124. Torregrosa JV, Félez I, Fuster D. Usefulness of imaging techniques in secondary hyperparathyroidism. Nefrologia 2010;30(2):158-67.
125. Llach F. The evolving pattern of calciphylaxis: therapeutic considerations. Nephrol Dial Transplant 2001;16(3):448-51.
126. Llach F. The evolving clinical features of calciphylaxis. Kidney Int 2003;57(Suppl 85):S122-124.
127. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2004;15(3):172-86.
128. Velasco N, MacGregor MS, Innes A, MacKay IG. Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? Nephrol Dial Transplant 2006;21:1999-2004.
129. Vassa N, Twardowski ZJ, Campbell J. Hyperbaric Oxigen therapy in calciphylaxis-induced skin necrosis in a peritoneal skin. Am J Kidney Dis 1994;23:878-81.
130. Podimow T, Wherrett C, Burns KD. Hyperbaric oxygen in the treatment of calciphylaxis, a case series. Nephrol Dial Transplant 2001;16:2176-80.
131. Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A. Hyperbaric oxygen therapy in the treatment of calcific uremic arteriolopathy, a case series. J Nephrol 2002;15:676-80.
132. Price PA, Faus SA, Williamson MK. Bisphosphonates Alendronate and Ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001;21:817-24.
133. Price PA, Omid N, Than NT, Williamson MK. The amino bisphosphonate Ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 2002;71:356-63.
134. Monney P, Nguyen QV, Perroud H. Rapid improvement of Calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 2004;19:2130-2.
135. Shiraishi N, Kitamura K, Miyoshi T, Adach M, Kohda Y, Nonoguchi H, et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006;48:151-4.
136. Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulphate. Am J Kidney Dis 2004;43:1104-8.
137. Hayden MR, Goldsmith DJ. Sodium thiosulfate: new hope for the treatment of calciphylaxis. Semin Dial 2010;23(3):258-62.